PLX (protalix.com) יחס שווי שוק לשווי בספרים

The price trend reflected in this chart complements the profit data, which stands at 2.79. Protalix BioTherapeutics (PLX) profitability relies on payments from global counterparties, creating effective leverage with low asset costs. The business utilizes an innovative method of protein synthesis in plants, ensuring stable demand for the therapy. The development of new agents is conducted jointly with major industry players.

For Protalix BioTherapeutics (PLX), whose commercialization is fully delegated to an external partner, the market-to-book ratio serves as an indicator of market confidence in the value of its intellectual assets. This coefficient is calculated as the ratio of the current market value of all shares to their book value, revealing the extent of overvaluation or undervaluation of the company's actual capital. This allows an investor to determine the fair margin of safety for the stock within the biopharmaceutical sector.